BANK OF AMERICA CORP /DE/ - LINEAGE CELL THERAPEUTICS IN ownership

LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 110 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q1 2022. The put-call ratio across all filers is 0.38 and the average weighting 0.1%.

Quarter-by-quarter ownership
BANK OF AMERICA CORP /DE/ ownership history of LINEAGE CELL THERAPEUTICS IN
ValueSharesWeighting
Q3 2023$7,557
-92.6%
6,404
-91.1%
0.00%
Q2 2023$101,816
-95.3%
72,210
-95.0%
0.00%
Q1 2023$2,165,669
+179772.8%
1,443,779
+140208.9%
0.00%
Q4 2022$1,204
+20.4%
1,029
+2.2%
0.00%
Q3 2022$1,000
-94.4%
1,007
-90.8%
0.00%
Q2 2022$18,000
+5.9%
11,0000.0%0.00%
Q1 2022$17,000
-80.2%
11,000
-68.8%
0.00%
Q4 2021$86,000
+196.6%
35,243
+204.0%
0.00%
Q3 2021$29,000
-40.8%
11,592
-33.5%
0.00%
Q2 2021$49,000
-25.8%
17,429
-37.8%
0.00%
Q1 2021$66,000
+187.0%
28,021
+116.1%
0.00%
Q4 2020$23,000
+91.7%
12,9640.0%0.00%
Q3 2020$12,000
-91.7%
12,964
-92.2%
0.00%
Q2 2020$145,000
+1015.4%
166,607
+938.8%
0.00%
Q1 2020$13,000
-43.5%
16,039
-37.0%
0.00%
Q4 2019$23,000
-41.0%
25,470
-37.6%
0.00%
Q3 2019$39,00040,8050.00%
Other shareholders
LINEAGE CELL THERAPEUTICS IN shareholders Q1 2022
NameSharesValueWeighting ↓
Defender Capital, LLC. 4,735,990$8,335,0003.63%
BROADWOOD CAPITAL INC 34,005,379$59,849,0003.55%
Prescott General Partners LLC 1,851,851$3,259,0000.14%
Strategic Wealth Investment Group, LLC 66,917$118,0000.07%
Laidlaw Wealth Management LLC 170,658$300,0000.06%
Humankind Investments LLC 26,737$47,0000.05%
DAFNA Capital Management LLC 80,000$141,0000.04%
Beirne Wealth Consulting Services, LLC 45,000$79,0000.04%
BRIDGEWAY CAPITAL MANAGEMENT, LLC 680,839$1,198,0000.02%
Allegheny Financial Group LTD 20,000$35,0000.02%
View complete list of LINEAGE CELL THERAPEUTICS IN shareholders